Literature DB >> 15994966

Analysis of hypoxia-related gene expression in sarcomas and effect of hypoxia on RNA interference of vascular endothelial cell growth factor A.

Kara Y Detwiller1, Namali T Fernando, Neil H Segal, Sandra W Ryeom, Patricia A D'Amore, Sam S Yoon.   

Abstract

Vascular endothelial cell growth factor A (VEGF-A) and hypoxia play important roles in tumor angiogenesis. VEGF-A gene expression is up-regulated in tumors under hypoxic conditions, yet it is unclear how such up-regulation will affect the efficacy of RNA interference strategies targeting VEGF-A. Four potential short interfering RNA (siRNA) sequences for the VEGF-A gene were cloned into expression plasmids and transfected into HT1080 human fibrosarcoma cells. Stable transfection of these plasmids decreased VEGF-A mRNA levels and protein secretion by up to 99%. Our analysis of >100 hypoxia-related genes using oligonucleotide microarrays of 38 human sarcoma samples and 14 normal tissues identified distinctly different patterns of expression between sarcomas and normal tissues as assessed by hierarchical clustering analysis. Numerous hypoxia-related genes were significantly up-regulated in sarcomas including hypoxia-inducible factor 1alpha (HIF-1alpha). Exposure of wild-type HT1080 cells to 1% hypoxia resulted in HIF-1alpha up-regulation and a 74% increase in VEGF-A secretion as compared with secretion under normoxic conditions. Surprisingly, stable cell lines expressing VEGF-A siRNAs silenced VEGF-A expression equally well in hypoxia and normoxia. S.c. injection of cells with VEGF-A siRNAs into athymic nude mice led to slower-growing tumors, decreased blood vessel density, and greater apoptosis when compared with controls. Immunofluorescence analysis of tumor sections revealed areas of HIF-1alpha nuclear expression, suggesting areas of hypoxia, in both control tumors and VEGF-suppressed tumors. We conclude that hypoxia plays an important role in human sarcomas but hypoxic up-regulation of VEGF-A expression does not attenuate the efficacy of VEGF-A RNA interference.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15994966     DOI: 10.1158/0008-5472.CAN-04-4078

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  62 in total

1.  Suppression of vascular endothelial growth factor via siRNA interference modulates the biological behavior of human nasopharyngeal carcinoma cells.

Authors:  Hai B Zhou; Yi F Yin; Yan Hu; Xin Li; Li Y Zou; Yong J Li; Yu Gu; Bao Q Ou; Juan Fu; Jun H Du; Gang Wu
Journal:  Jpn J Radiol       Date:  2011-09-29       Impact factor: 2.374

2.  Fructose-1,6-Bisphosphatase 2 Inhibits Sarcoma Progression by Restraining Mitochondrial Biogenesis.

Authors:  Peiwei Huangyang; Fuming Li; Pearl Lee; Itzhak Nissim; Aalim M Weljie; Anthony Mancuso; Bo Li; Brian Keith; Sam S Yoon; M Celeste Simon
Journal:  Cell Metab       Date:  2019-11-21       Impact factor: 27.287

Review 3.  [Sarcoma gene signatures].

Authors:  F Chibon; J-M Coindre
Journal:  Pathologe       Date:  2011-02       Impact factor: 1.011

4.  Differential effects of VEGFR-1 and VEGFR-2 inhibition on tumor metastases based on host organ environment.

Authors:  Yoon-Jin Lee; Daniel L Karl; Ugwuji N Maduekwe; Courtney Rothrock; Sandra Ryeom; Patricia A D'Amore; Sam S Yoon
Journal:  Cancer Res       Date:  2010-10-26       Impact factor: 12.701

5.  miR-181a-5p Inhibits Cancer Cell Migration and Angiogenesis via Downregulation of Matrix Metalloproteinase-14.

Authors:  Yiyi Li; Cem Kuscu; Anna Banach; Qian Zhang; Ashleigh Pulkoski-Gross; Deborah Kim; Jingxuan Liu; Eric Roth; Ellen Li; Kenneth R Shroyer; Paula I Denoya; Xiaoxia Zhu; Longhua Chen; Jian Cao
Journal:  Cancer Res       Date:  2015-05-14       Impact factor: 12.701

Review 6.  Sulf-2: an extracellular modulator of cell signaling and a cancer target candidate.

Authors:  Steven D Rosen; Hassan Lemjabbar-Alaoui
Journal:  Expert Opin Ther Targets       Date:  2010-09       Impact factor: 6.902

7.  The emerging role of CXCL10 in cancer (Review).

Authors:  Mingli Liu; Shanchun Guo; Jonathan K Stiles
Journal:  Oncol Lett       Date:  2011-05-09       Impact factor: 2.967

8.  Expression of RNA interference triggers from an oncolytic herpes simplex virus results in specific silencing in tumour cells in vitro and tumours in vivo.

Authors:  Anna-Maria Anesti; Guy R Simpson; Toby Price; Hardev S Pandha; Robert S Coffin
Journal:  BMC Cancer       Date:  2010-09-13       Impact factor: 4.430

9.  Analysis of multiple sarcoma expression datasets: implications for classification, oncogenic pathway activation and chemotherapy resistance.

Authors:  Panagiotis A Konstantinopoulos; Elena Fountzilas; Jeffrey D Goldsmith; Manoj Bhasin; Kamana Pillay; Nancy Francoeur; Towia A Libermann; Mark C Gebhardt; Dimitrios Spentzos
Journal:  PLoS One       Date:  2010-04-01       Impact factor: 3.240

10.  Cross species genomic analysis identifies a mouse model as undifferentiated pleomorphic sarcoma/malignant fibrous histiocytoma.

Authors:  Jeffrey K Mito; Richard F Riedel; Leslie Dodd; Guy Lahat; Alexander J Lazar; Rebecca D Dodd; Lars Stangenberg; William C Eward; Francis J Hornicek; Sam S Yoon; Brian E Brigman; Tyler Jacks; Dina Lev; Sayan Mukherjee; David G Kirsch
Journal:  PLoS One       Date:  2009-11-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.